Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 24,925 shares of the company's stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $4.81, for a total transaction of $119,889.25. Following the sale, the insider directly owned 401,891 shares of the company's stock, valued at $1,933,095.71. The trade was a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The stock was sold at an average price of $4.97, for a total value of $21,261.66.
- On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The stock was sold at an average price of $4.10, for a total value of $22,791.90.
- On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The stock was sold at an average price of $4.04, for a total value of $15,352.00.
- On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total value of $23,483.18.
- On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The stock was sold at an average price of $4.32, for a total value of $66,026.88.
- On Wednesday, January 28th, Chidozie Ugwumba sold 8,717 shares of Clene stock. The stock was sold at an average price of $4.91, for a total value of $42,800.47.
- On Tuesday, January 27th, Chidozie Ugwumba sold 4,139 shares of Clene stock. The stock was sold at an average price of $5.08, for a total value of $21,026.12.
- On Monday, January 26th, Chidozie Ugwumba sold 6,418 shares of Clene stock. The stock was sold at an average price of $5.02, for a total value of $32,218.36.
- On Friday, January 23rd, Chidozie Ugwumba sold 5,556 shares of Clene stock. The stock was sold at an average price of $5.27, for a total value of $29,280.12.
- On Thursday, January 22nd, Chidozie Ugwumba sold 12,665 shares of Clene stock. The stock was sold at an average price of $5.32, for a total transaction of $67,377.80.
Clene Trading Up 12.5%
Clene stock opened at $5.76 on Tuesday. The firm has a 50 day moving average of $5.00 and a 200 day moving average of $6.65. The firm has a market capitalization of $67.85 million, a price-to-earnings ratio of -2.22 and a beta of 0.62. Clene Inc. has a 12-month low of $2.28 and a 12-month high of $13.50.
Clene (NASDAQ:CLNN - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.03 million. On average, analysts predict that Clene Inc. will post -5.19 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CLNN. SymBiosis Capital Partners LLC purchased a new position in shares of Clene during the fourth quarter valued at about $4,523,000. Scoggin Management LP grew its holdings in shares of Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company's stock valued at $1,506,000 after purchasing an additional 107,250 shares in the last quarter. Ensign Peak Advisors Inc grew its holdings in shares of Clene by 668.6% in the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company's stock valued at $671,000 after purchasing an additional 99,481 shares in the last quarter. PEAK6 LLC purchased a new position in shares of Clene in the fourth quarter valued at $294,000. Finally, State Street Corp grew its holdings in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company's stock valued at $175,000 after purchasing an additional 17,300 shares in the last quarter. Hedge funds and other institutional investors own 23.28% of the company's stock.
Analyst Ratings Changes
CLNN has been the subject of several analyst reports. Canaccord Genuity Group reissued a "buy" rating and issued a $48.00 target price on shares of Clene in a report on Friday, March 13th. D. Boral Capital reiterated a "buy" rating and issued a $23.00 price target on shares of Clene in a research note on Thursday, March 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Clene in a research note on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $32.60.
Get Our Latest Stock Report on CLNN
About Clene
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
